VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update
ISNES, Belgium, March 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onThursday, March 14 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2018, in conjunction with the f...
VolitionRx Limited to Expand its Nu.Q(TM) Trials to Veterinary Diagnostics
ISNES, Belgium, Oct. 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced very encouraging preliminary results from a proof of concept study using its Nu.Q™ diagnostic test in veterinary medicine at the 10th anniversary meeting of the Belgian Technology Mi...
VolitionRx Limited Releases Video Featuring Interviews with its Scientific Advisory Board
ISNES, Belgium, Sept. 26 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today released a video featuring members of its Scientific Advisory Board (SAB). The video was taken at Volition's laboratories inBelgium during the last SAB meeting and features members of the SAB...
VolitionRx Limited to Attend Multiple Conferences in September
ISNES, Belgium, Sept. 5, 2018 /PRNewswire/ -- VolitionRx Limited
Preliminary Data from Study Demonstrates 94% Accuracy in Detecting Aggressive Prostate Cancer
ISNES, Belgium, Aug. 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Q™ assays to diagnose men with high-grade prostate cancer. Vo...
VolitionRx Announces $9 Million Private Placement
ISNES, Belgium, Aug. 8, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a definitive agreement with an existing accredited investor related to a private placement offering (PIPE) of 5 million shares of Volition common stock at a ...
VolitionRx Limited Schedules Second Quarter 2018 Earnings Conference Call and Business Update
ISNES, Belgium, Aug. 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onTuesday, August 14 at 8:30 a.m. Eastern time to discuss its financial and operating results from the second quarter of 2018, in conjunction with the filing of its...
VolitionRx's First Research Use Only Product Is "On-The-Shelf" Today
ISNES, Belgium, Aug. 1, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its first product the "Total Nu.Q™ Assay" research use only (RUO) kit, is ready and available for purchase through Active Motif, its Global Sales and Distribution Partner ( http...
Volition Secures Additional $700,000 Non-Dilutive Funding from the Walloon Region
ISNES, Belgium, July 2, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding of approximately$700,000 from the Walloon Regional Government. Including this latest amount, Volition has received approximat...
VolitionRx Limited to Attend the Bank of America Merrill Lynch 2018 Health Care Conference from May 15-17, 2018
ISNES, Belgium, May 14, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced its participation in the Bank of America Merrill Lynch 2018 Health Care Conference being held fromMay 15-17, 2018 at the Encore Hotel inLas Vegas, NV. Scott Powell, Executive Vice ...
VolitionRx Limited Announces First Quarter 2018 Financial Results and Business Update
ISNES, Belgium, May 10, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced financial results and a business update for the first quarter endedMarch 31, 2018. Volition management will host a conference call tomorrow,May 11, at 8:30 a.m. U.S. Eastern Time to ...
VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits
ISNES, Belgium, May 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has entered into a Global Sales and Distribution Agreement with Active Motif for a range of Research Use Only ("RUO") kits, that are based on its proprietary Nucleosomics® tec...
VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update
Conference call to take place Friday, May 11, 2018 at 8:30 am Eastern time ISNES, Belgium, May 4, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Friday, May 11 at 8:30 a.m. Eastern time to discuss its financial and opera...
VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock
ISNES, Belgium, March 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the closing of its prev...
VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock
ISNES, Belgium, March 9, 2018 /PRNewswire/ -- VolitionRx Limited
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
NAMUR, Belgium, March 8, 2018 /PRNewswire/ -- VolitionRx Limited
VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board
ISNES, Belgium, March 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has further strengthened its Scientific Advisory Board with the addition of Dr.Lee-Jen Wei, a professor of Biostatistics atHarvard University. Prof. Wei's main area of rese...
VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update
Conference call to take place Friday, March 2, 2018 at 8:30 am Eastern time ISNES, Belgium, Feb. 28, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference call onFriday, March 2 at 8:30 a.m. Eastern time to discuss its financial and operating res...
VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer
* Study demonstrates high detection rates of Stage I cancer and pre-cancerous adenomas in colorectal cancer screening trial for Nu.QTM blood test * Conference call to discuss interim results scheduled for Tuesday, February 27 at 8:30 a.m. Eastern Time ISNES, Belgium, Feb. 26, 2018 /PRNewswire/...
VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.
ISNES, Belgium, Feb. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the successful conclusion to the Logistics and Pathway Design Study conducted by Hvidovre Hospital and The Danish Research Group. The study was established to answer the very practi...
